ONE Bio Launches Branded Sweetener, "Sero," Based on Stevia
16 December 2010 - 12:00AM
Marketwired
ONE Bio, Corp. ("ONE" or the "Company") (OTCBB: ONBI), an
innovative company utilizing green process manufacturing to produce
raw chemicals and herbal extracts, natural and health supplements
and organic products, announces the launch of its own trademarked
brand of sweetener product using Stevia. The new product, a zero
calorie over-the-counter sweetener, is called
Sero (Serial no. 77-931,158). The launch of
Sero follows the announcement of a record breaking 3rd
quarter for ONE Bio bringing year-to-date revenue and net income to
$37.3 million and $5.9 million respectively (a 333% and 185%
increase compared to the same period a year ago).
Stevia is widely used in soft drinks, health supplements,
desserts, canned products, and sold as a pre-packaged sweetener on
supermarket shelves worldwide. Stevia has received a lot of
attention since its introduction because it is sweeter and believed
to be healthier than sugar and other substitutes. Aspartame is the
number one sugar substitute in the United States, but it has been
linked to tumors, seizures, blindness and mood swings. Japan has
used the Stevia sweetener for decades and it now comprises forty
percent (40%) of the sweeteners used there.
Mintel International Group Ltd., a leading market research firm,
in their press release dated Sept 2009 predicted that the stevia
market could reach $2 billion by the end of 2011. In the same
article Mintel also stated that since December 2008, when the FDA
approved use of rebaudioside A (an active ingredient of stevia) in
US food and beverage, the stevia market has surged. The article
states that "by mid-July 2009, stevia sales topped $95 million, a
substantial increase over the $21 million achieved in all of
2008."
"China is the largest producer and manufacturer of sugar in the
world, and with our extensive customer base and our expertise in
cultivating Stevia, we expect Sero to become
another high margin and high demand product in our portfolio.
Sero's competitive advantage lies in the
ingredients used to rid the after-taste and lower production costs
making the product attractive to consumers and competitively
priced," stated ONE's CEO Marius Silvasan.
"Our distributors responded positively to our launch and we've
taken several pre-orders to date. Our market survey into
supermarkets in China has been encouraging and we also expect
strong demand for Sero outside of China especially in the United
States, Europe and Latin America. We intend to expand our
distribution in those areas early next year," added Silvasan.
About ONE Bio, Corp. ONE Bio, Corp.
("ONE") (OTCBB: ONBI) (www.onehcorp.com) headquartered in Miami,
FL, is an innovative company utilizing patented green process
manufacturing to produce raw chemicals and herbal extracts, natural
supplements and organic products. ONE is focused on the Asia
Pacific region. Key products include widely recognized Solanesol,
CoQ10, Resveratrol and 5-HTP, organic fertilizers, and organic
bamboo health food and beverages. ONE has experienced solid organic
growth driven by a robust demand for its products in China, Japan
and the United States.
This press release includes statements that constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Reform Act"). ONE
Bio, Corp. claims the protection of the safe-harbor for
forward-looking statements contained in the Reform Act. These
forward-looking statements are often characterized by the terms
"may," "believes," "projects," "expects," or "anticipates," and do
not reflect historical facts. Specific forward-looking statements
contained in this press release include, but are not limited to:
our successful integration of diversified growth companies, impact
of the company's expansion plan, and new business development
success, future financial results, development and acquisition of
new product lines and services, the impact of competitive products
or pricing from technological changes, the effect of economic
conditions and other uncertainties. The forward-looking statements
contained herein involve risks and uncertainties that could cause
actual results to differ materially from the expectations contained
in any such forward-looking statements. These risks include, but
are not limited to: failure to manage operating expenses or
integrate new companies and/or technologies, each of which could
have a material impact on our business, our financial results, and
the company's stock price. These risks and other factors are
detailed in the Company's regular filings with the U.S. Securities
and Exchange Commission. Most of these factors are difficult to
predict accurately and are generally beyond the Company's control.
Forward-looking statements speak only as to the date they are made
and ONE Bio, Corp. does not undertake to update forward-looking
statements to reflect circumstances or events that occur after the
date the forward-looking statements are made.
Company Contact: Jeanne Chan Senior VP Tel. +888.676.4445
jchan@onehcorp.com
One Bio (CE) (USOTC:ONBI)
Historical Stock Chart
From Jun 2024 to Jul 2024
One Bio (CE) (USOTC:ONBI)
Historical Stock Chart
From Jul 2023 to Jul 2024